Abiopharma

INSIGHT MOLECULAR DIAGNOSTICS INC. (IMDX) Reports the reporting period Financial Results INSIGHT MOLECULAR DIAGNOSTICS INC. (IMDX) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 1916
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 18728
  • anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. FDA CAUTION: This press release concerns certain products that are under clinical investigation, and which have not yet been cleared or authorized for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated. Investor Contact: Douglas Farrell LifeSci Advisors LLC imdx@lifesciadvisors.com 9 Financial Tables Follow INSIGHT MOLECULAR DIAGNOSTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) June 30, 2026